Novo Nordisk files lawsuit against Eli Lilly over GLP-1 marketing claims

Novo Nordisk has initiated legal action against Eli Lilly, alleging the use of deceptive advertising and outdated clinical data to misrepresent the efficacy of competing GLP-1 drugs. The litigation highlights intensifying competition in the obesity and diabetes pharmaceutical market, though the impact on drug market share remains uncertain.